Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...
This approval marks a significant milestone as it expands the treatment’s availability to 33 countries, enhancing ImmunityBio’s global commercial presence. ANKTIVA in combination with BCG is now the ...
After more than doubling its share price in just five days last week, ImmunityBio’s stock rocketed higher again today, finishing up 17%. The catalyst for this was the company’s FDA End-of-Phase ...
The company plans to submit a BLA for BCG-naive bladder cancer in Q4 2026, based on interim data showing an 84% complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results